FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3005033819> ?p ?o ?g. }

• W3005033819 endingPage "11" @default.
• W3005033819 startingPage "11" @default.
• W3005033819 abstract "11 Background: Ilixadencel is a cell-based allogeneic off-the-shelf product aimed to prime anti-cancer immune response when injected intratumorally. The present randomized Phase II multicenter trial (MERECA; NCT02432846) evaluated intratumoral ilixadencel administration (2 doses 2 weeks apart) pre-nephrectomy followed by sunitinib post-nephrectomy compared with sunitinib monotherapy post-nephrectomy as first-line systemic therapy in patients with newly diagnosed synchronous metastatic renal cell carcinoma (mRCC). Methods: Patients were randomly assigned at two-to-one ratio to the combination (COMBO) or sunitinib (SUN) arm. Overall survival (OS) was assessed from enrollment while progression free survival (PFS) and tumor response was assessed per RECIST 1.1 (independent blinded central review) from start of sunitinib. Results: From April 2014 to January 2017, 88 patients (58 COMBO, 30 SUN) were randomized. In the COMBO arm, 2 patients did not receive ilixadencel, 10 did not receive sunitinib, and 1 did not have any follow up CT-scan. Five patients in the SUN arm never received sunitinib. Five patients (11%) in the COMBO arm had a complete response as best response versus one patient (4%) in the SUN arm. Confirmed ORR was 42.2 % (19/45) versus 24.0% (6/25). Median Duration of Response was 7.1 months versus 2.9 months. Median PFS was 11.8 months versus 11.0 months. Median OS has still not been reached in either group. As of July 2019, 57% and 43% were alive in the COMBO and SUN arms, respectively. Treatment with ilixadencel did not add any treatment-related Grade 3-4 Adverse Events. Conclusions: Compared to sunitinib monotherapy, combined treatment with ilixadencel followed by sunitinib demonstrated higher confirmed ORR, including several complete responses and longer duration of response, in patients with newly diagnosed synchronous mRCC. Clinical trial information: 02432846." @default.
• W3005033819 created "2020-02-14" @default.
• W3005033819 creator A5001340494 @default.
• W3005033819 creator A5001812156 @default.
• W3005033819 creator A5006662920 @default.
• W3005033819 creator A5009247683 @default.
• W3005033819 creator A5009523282 @default.
• W3005033819 creator A5017073028 @default.
• W3005033819 creator A5030712482 @default.
• W3005033819 creator A5035036126 @default.
• W3005033819 creator A5038937574 @default.
• W3005033819 creator A5046751920 @default.
• W3005033819 creator A5049249562 @default.
• W3005033819 creator A5052385412 @default.
• W3005033819 creator A5057705931 @default.
• W3005033819 creator A5058855375 @default.
• W3005033819 creator A5064442357 @default.
• W3005033819 creator A5077359552 @default.
• W3005033819 creator A5082828068 @default.
• W3005033819 creator A5083328412 @default.
• W3005033819 creator A5085773910 @default.
• W3005033819 creator A5086215558 @default.
• W3005033819 date "2020-02-10" @default.
• W3005033819 modified "2023-10-15" @default.
• W3005033819 title "A randomized phase II study with ilixadencel, a cell-based immune primer, plus sunitinib versus sunitinib alone in synchronous metastatic renal cell carcinoma." @default.
• W3005033819 doi "https://doi.org/10.1200/jco.2020.38.5_suppl.11" @default.
• W3005033819 hasPublicationYear "2020" @default.
• W3005033819 type Work @default.
• W3005033819 sameAs 3005033819 @default.
• W3005033819 citedByCount "8" @default.
• W3005033819 countsByYear W30050338192021 @default.
• W3005033819 countsByYear W30050338192022 @default.
• W3005033819 countsByYear W30050338192023 @default.
• W3005033819 crossrefType "journal-article" @default.
• W3005033819 hasAuthorship W3005033819A5001340494 @default.
• W3005033819 hasAuthorship W3005033819A5001812156 @default.
• W3005033819 hasAuthorship W3005033819A5006662920 @default.
• W3005033819 hasAuthorship W3005033819A5009247683 @default.
• W3005033819 hasAuthorship W3005033819A5009523282 @default.
• W3005033819 hasAuthorship W3005033819A5017073028 @default.
• W3005033819 hasAuthorship W3005033819A5030712482 @default.
• W3005033819 hasAuthorship W3005033819A5035036126 @default.
• W3005033819 hasAuthorship W3005033819A5038937574 @default.
• W3005033819 hasAuthorship W3005033819A5046751920 @default.
• W3005033819 hasAuthorship W3005033819A5049249562 @default.
• W3005033819 hasAuthorship W3005033819A5052385412 @default.
• W3005033819 hasAuthorship W3005033819A5057705931 @default.
• W3005033819 hasAuthorship W3005033819A5058855375 @default.
• W3005033819 hasAuthorship W3005033819A5064442357 @default.
• W3005033819 hasAuthorship W3005033819A5077359552 @default.
• W3005033819 hasAuthorship W3005033819A5082828068 @default.
• W3005033819 hasAuthorship W3005033819A5083328412 @default.
• W3005033819 hasAuthorship W3005033819A5085773910 @default.
• W3005033819 hasAuthorship W3005033819A5086215558 @default.
• W3005033819 hasConcept C126322002 @default.
• W3005033819 hasConcept C126894567 @default.
• W3005033819 hasConcept C141071460 @default.
• W3005033819 hasConcept C143998085 @default.
• W3005033819 hasConcept C2777472916 @default.
• W3005033819 hasConcept C2779490328 @default.
• W3005033819 hasConcept C2780091579 @default.
• W3005033819 hasConcept C2780227381 @default.
• W3005033819 hasConcept C2781068499 @default.
• W3005033819 hasConcept C31760486 @default.
• W3005033819 hasConcept C535046627 @default.
• W3005033819 hasConcept C71924100 @default.
• W3005033819 hasConcept C90924648 @default.
• W3005033819 hasConceptScore W3005033819C126322002 @default.
• W3005033819 hasConceptScore W3005033819C126894567 @default.
• W3005033819 hasConceptScore W3005033819C141071460 @default.
• W3005033819 hasConceptScore W3005033819C143998085 @default.
• W3005033819 hasConceptScore W3005033819C2777472916 @default.
• W3005033819 hasConceptScore W3005033819C2779490328 @default.
• W3005033819 hasConceptScore W3005033819C2780091579 @default.
• W3005033819 hasConceptScore W3005033819C2780227381 @default.
• W3005033819 hasConceptScore W3005033819C2781068499 @default.
• W3005033819 hasConceptScore W3005033819C31760486 @default.
• W3005033819 hasConceptScore W3005033819C535046627 @default.
• W3005033819 hasConceptScore W3005033819C71924100 @default.
• W3005033819 hasConceptScore W3005033819C90924648 @default.
• W3005033819 hasIssue "5_suppl" @default.
• W3005033819 hasLocation W30050338191 @default.
• W3005033819 hasOpenAccess W3005033819 @default.
• W3005033819 hasPrimaryLocation W30050338191 @default.
• W3005033819 hasRelatedWork W2166689662 @default.
• W3005033819 hasRelatedWork W2286005466 @default.
• W3005033819 hasRelatedWork W2551353941 @default.
• W3005033819 hasRelatedWork W2891281296 @default.
• W3005033819 hasRelatedWork W2922087791 @default.
• W3005033819 hasRelatedWork W2965179065 @default.
• W3005033819 hasRelatedWork W3033178514 @default.
• W3005033819 hasRelatedWork W3142535259 @default.
• W3005033819 hasRelatedWork W3174785964 @default.
• W3005033819 hasRelatedWork W4283452074 @default.
• W3005033819 hasVolume "38" @default.
• W3005033819 isParatext "false" @default.
• W3005033819 isRetracted "false" @default.
• W3005033819 magId "3005033819" @default.

• next